Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
TCRR.US
id: 610

TCRR M&A Deal with ADAP Case

  • $TCRR and $ADAP announced an all-stock merger.

  • TCR² Therapeutics stockholders will own ~25% of the combined company.

  • $TCRR Investors suspect that pricing terms of the M&A deal with $ADAP are unfair.

On March 6, 2023, Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction.

Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company.

Investors of $TCRR may have reasons to suspect that the pricing terms of the M&A transaction with $ADAP are unfair and that the Company BoD breached fiduciary duties to shareholders.

Case Status
Inactive Investigation
Alleged Offence
Mismanagement, 
Financial Misrepresentation, 
Fraud, 
Malpractice, 
Negligence, 
Breach of Fiduciary duty, 
Omissions
Suspected Party
Directors, 
Management, 
Investment Bank, 
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
03/06/2023